Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015977 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00015977 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 13 participants.
The verdict
NCT00015977, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining vaccine therapy with interleukin-12 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy combined with interleukin-12 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Interventions
- BIOLOGICAL recombinant interleukin-12
- BIOLOGICAL PSA prostate cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2001-11 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015977
The ClinicalTrials.gov registry entry for NCT00015977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interleukin-12 is the first listed.
NCT00015977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00015977 about?
NCT00015977 is a clinical study titled "Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy". RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining vaccine therapy with i...
What is the current status of trial NCT00015977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2001-11. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00015977?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL), PSA prostate cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00015977?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.